Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

SHE/002332 stock hub

SHE/002332 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SHE/002332is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.7B

Shenzhen Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

SHE/002332

In the news

Latest news · SHE/002332

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E18.6

P25 17.1P50 24.2P75 37.8

Trailing P/E22.1

P25 23.5P50 41.3P75 83.2

ROE6.6

P25 -0.9P50 4.1P75 8.8

ROIC6.3

P25 -0.5P50 5P75 11.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SHE/002332 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

239

Groups with data

Currency

CNY

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	China
Country code	CN
Employees	3,205
Employees Change	-76%
Employees Change Percent	-2.32
Enterprise value	CNY 7.7B
Exchange	Shenzhen Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	CNE100000K64
Last refreshed	2026-05-10
Market cap	CNY 8.7B
Price	CNY 8.83
Price currency	CNY
Rev Per Employee	1,144,811.26x
Sector	Healthcare
Sic	2834
Symbol	she/002332
Website	https://www.xjpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.57%
EV Earnings	19.3x
EV/EBIT	17.09x
EV/EBITDA	11.48x
EV/FCF	42.54x
EV/Sales	2.1x
FCF yield	2.07%
Forward P/E	18.59x
P/B ratio	1.43x
P/E ratio	22.08x
P/S ratio	2.38x
PE Ratio10 Y	27.14x
PE Ratio3 Y	22.17x
PE Ratio5 Y	20.15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	10.47%
EBITDA Margin	16.27%
FCF margin	4.94%
Gross margin	61.32%
Gross Profit	CNY 2.3B
Gross Profit Growth	0.34%
Gross Profit Growth Q	-2.16%
Gross Profit Growth3 Y	-2.23%
Gross Profit Growth5 Y	-1.21%
Net Income	CNY 399.5M
Net Income Growth	2.44%
Net Income Growth Q	-34.79%
Net Income Growth Years	1%
Net Income Growth3 Y	-19.11%
Net Income Growth5 Y	-6.12%
Pretax Margin	13.25%
Profit Margin	10.89%
Profit Per Employee	CNY 124,662
Profitable Years	20
ROA	3.34
Roa5y	5.46
ROCE	6.14
ROE	6.64
Roe5y	10.33
ROIC	6.31
Roic5y	12.05

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	3.86%
Cagr15y	2.9%
Cagr1y	1.16%
Cagr3y	-13.65%
Cagr5y	-6.76%
Div CAGR10	19.62%
Div CAGR3	38.67%
Div CAGR5	31.95%
EPS Growth	1.78
EPS Growth Q	-34.82
EPS Growth Years	1
EPS Growth3 Y	-19.1
EPS Growth5 Y	-7.49
FCF Growth	156.73%
FCF Growth3 Y	-24.09%
FCF Growth5 Y	-22.65%
OCF Growth	18.11%
OCF Growth Q	631.66%
OCF Growth10 Y	3.53%
OCF Growth3 Y	-18.52%
OCF Growth5 Y	-13.67%
Revenue Growth	-7.6x
Revenue Growth Q	-8.91x
Revenue Growth Years	0x
Revenue Growth3 Y	-5.06x
Revenue Growth5 Y	-3.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	CNY 0.51
Assets	CNY 7.3B
Cash	CNY 1.2B
Current Assets	CNY 3.4B
Current Liabilities	CNY 1B
Debt	CNY 148.4M
Debt EBITDA	CNY 0.25
Debt Equity	CNY 0.02
Debt FCF	CNY 0.82
Equity	CNY 6.1B
Interest Coverage	82.71
Liabilities	CNY 1.1B
Long Term Assets	CNY 3.9B
Long Term Liabilities	CNY 132.7M
Net Cash	CNY 1.1B
Net Cash By Market Cap	CNY 12.23
Net Cash Growth	-17.84%
Net Debt EBITDA	CNY -1.79
Net Debt Equity	CNY -0.17
Net Debt FCF	CNY -5.89
Tangible Book Value	CNY 5.3B
Tangible Book Value Per Share	CNY 5.38
WACC	5.65

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.32
Inventory Turnover	1.56
Net Working Capital	CNY 1.3B
Quick ratio	2.37
Working Capital	CNY 2.3B
Working Capital Turnover	CNY 1.48

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.64%
Dividend Growth	0%
Dividend Growth Years	1%
Dividend per share	CNY 0.4
Dividend Years	11
Dividend Yield	4.53%
Ex Div Date	2025-10-22
Last Dividend	CNY 0.1
Payout Frequency	Annual
Payout Ratio	100.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	46.02%
1Y total return	1.16%
200-day SMA	9.62
3Y total return	-35.62%
50-day SMA	9.01
50-day SMA vs 200-day SMA	50under200
5Y total return	-29.54%
All Time High	19.9
All Time High Change	-55.63%
All Time High Date	2015-06-03
All Time Low	3.6
All Time Low Change	145.55%
All Time Low Date	2012-12-04
ATR	0.13
Beta	0.26
Beta1y	0.22
Beta2y	0.41
Ch YTD	-2
High	8.86
High52	11.79
High52 Date	2025-08-21
High52ch	-25.11%
Low	8.79
Low52	8.58
Low52 Date	2026-03-23
Low52ch	2.91%
Ma50ch	-2%
Price vs 200-day SMA	-8.21%
RSI	43.89
RSI Monthly	41.67
RSI Weekly	38.37
Sharpe ratio	-0.06x
Sortino ratio	0.18
Total Return	3.89%
Tr YTD	-2
Tr15y	53.6%
Tr1m	-2.75%
Tr1w	0.57%
Tr3m	-4.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	CNY 384.2M
Operating Income Growth	-38.41
Operating Income Growth Q	-25.21
Operating Income Growth3 Y	-17.23
Operating Income Growth5 Y	-11.34
Operating margin	10.47

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	775,983,058%
Net Borrowing	86,167,060
Shares Institutions	12.64%
Shares Out	989,204,866
Shares Qo Q	-3.86%
Shares Yo Y	0.64%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	CNY 181.2M
Average Volume	11,148,492.5x
Bv Per Share	6.14
CAPEX	CNY -182.6M
Ch10y	24.95
Ch15y	23.39
Ch1m	-2.75
Ch1w	0.57
Ch1y	-3.07
Ch3m	-4.85
Ch3y	-41.02
Ch5y	-37.2
Ch6m	-7.73
Change	0.23%
Change From Open	0
Close	8.81
Days Gap	0.23
Depreciation Amortization	212,725,330
Dollar Volume	47,875,006.1
Earnings Date	2026-04-23
EBIT	CNY 384.2M
EBITDA	CNY 596.9M
EPS	CNY 0.4
F Score	5
FCF	CNY 181.2M
FCF EV Yield	2.35x
FCF Per Share	CNY 0.18
Financing CF	-316,297,506
Fiscal Year End	December
Founded	1,972
Goodwill	614,368,449
Graham Number	7.43478
Graham Upside	-15.8
Income Tax	CNY 81.5M
Investing CF	-168,066,173
Is Primary Listing	1
Last Earnings Date	2026-04-23
Last Report Date	2026-03-31
Last Split Date	2017-05-18
Last Split Type	Forward
Lynch Fair Value	CNY 2
Lynch Upside	-77.36
Ma150	9.3
Ma150ch	-5.06%
Ma20	8.93
Ma20ch	-1.08%
Net CF	-140,140,770
Next Earnings Date	2026-08-27
Open	8.83
P FCF Ratio	48.19
P OCF Ratio	24.01
Payment Date	2025-10-22
Position In Range	57.14
Ppne	2,811,737,328
Price Date	2026-05-08
Price EBITDA	CNY 14.63
Ptbv Ratio	1.64
Relative Volume	0.49x
Revenue	3,669,120,088x
Tax By Revenue	2.22x
Tax Rate	16.75%
Tr6m	-7.73%
Volume	5,421,858

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

SHE/002332 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+4.5%

$0.40 annual per share

Payout ratio

+100.6%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+32.0%

1 consecutive years of growth

Total shareholder yield

+3.9%

Next ex-dividend date: 2025-10-22

Performance

SHE/002332 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SHE/002332?

Insider, institutional, and short-interest positioning.

Institutional ownership

+12.6%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.6%

Negative means the company is buying back shares.

Technical

SHE/002332 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.9

Neutral momentum band

Price vs 200-day MA

-8.2%

50/200-day relationship not available

Beta (5Y)

0.26

Less volatile than the market

Sharpe ratio

-0.06

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SHE/002332

Hub-level FAQ points readers to the deeper analysis pages.

What is the current she/002332 stock rating?

she/002332 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full she/002332 analysis?

The full report lives at /stocks/she/002332/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for she/002332?

The latest report frames she/002332 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the she/002332 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.